SCHEMBL6080358

SCHEMBL6080358

COC(=O)c1cc(OCc2ccccc2)c2cc(C#Cc3cccnc3)cc([N+](=O)[O-])c2n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.43
CYP11B2 P19099 3/20 0.43
CYP19A1 P11511 1/20 0.43
MAPT P10636 2/20 0.42
APP P05067 1/20 0.40
KMT2A Q03164 3/20 0.40
PDCD1 Q15116 2/20 0.39
CD274 Q9NZQ7 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
LRRK2 Q5S007 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 2/20 0.38
PTGES O14684 1/20 0.37
SGMS2 Q8NHU3 1/20 0.37
CTSV O60911 1/20 0.37
CTSL P07711 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080661 0.93 APP (0.43) CYP19A1MAPTAPPKMT2AALDH1A1
SCHEMBL6593975 0.91 CYP11B1 (0.46) CYP11B1CYP11B2CYP19A1KMT2APDCD1
SCHEMBL6080214 0.86 APP (0.43) CYP19A1MAPTAPPKMT2APDCD1
SCHEMBL6080108 0.86 APP (0.41) CYP19A1MAPTAPPKMT2AALDH1A1
SCHEMBL6595140 0.84 CTSV (0.42) CYP19A1MAPTAPPKMT2AMEN1
SCHEMBL6595150 0.84 CTSV (0.42) CYP19A1MAPTAPPKMT2AMEN1
SCHEMBL6079222 0.83 APP (0.41) CYP19A1MAPTAPPKMT2APDCD1
SCHEMBL6079326 0.81 APP (0.45) CYP19A1MAPTAPPKMT2AALDH1A1
SCHEMBL6079319 0.81 APP (0.45) CYP19A1MAPTAPPKMT2AALDH1A1
SCHEMBL6080613 0.80 CTSV (0.47) CYP19A1MAPTAPPKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL CYP11B1 633/4885CYP11B2 477/4885CYP19A1 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.